scholarly journals Mitral Stenosis: Making the diagnosis

2021 ◽  
Vol 8 (5) ◽  
pp. 01-03
Author(s):  
Sandhya Venugopal ◽  
Ezra A. Amsterdam ◽  
Patricia Applegate ◽  
Muhammad Majid ◽  
Ali Abdulraheem Mahdi ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Stenosis ◽  
Developing Nations ◽  
Ample Evidence ◽  
Percutaneous Balloon ◽  
The Us ◽  
History Of ◽  
Surgical Valve Replacement ◽  
Mitral Valve Calcification ◽  
Rheumatic Heart

The case of a 60-year-old man illustrates a number of important features of rheumatic heart disease (RHD). The patient’s age of presentation was late (>50 yo) and he had no history of predisposing condition for RHD but served in the South Pacific when he was in the US Navy. RHD was limited to mitral stenosis in this patient and his presentation of heart failure was late. His ECG revealed ample evidence of right ventricular enlargement, and echocardiography demonstrated severe mitral stenosis, enlarged right ventricle and right atrium and marked pulmonary hypertension. Because percutaneous balloon mitral valve commissurotomy was precluded by the degree of mitral valve calcification, he underwent successful surgical valve replacement with relief of symptoms. Although RHD is rarely encountered in North America and Europe, it remains a major cause of mortality in the developing nations.

scholarly journals Immediate Outcome of Percutaneous Balloon Mitral Valvotomy in Shahid Gangalal National Heart Centre, Bansbari, Kathmandu, Nepal

2015 ◽  
Vol 12 (1) ◽  
pp. 11-14 ◽  
Author(s):  
Nagma Shrestha ◽  
Yadav Kumar Dev Bhatta ◽  
Arun Maskey ◽  
Rabi Malla ◽  
Rajib Rajbhandari ◽  
...  
Keyword(s):  
Mitral Stenosis ◽  
Effective Procedure ◽  
Safety And Efficacy ◽  
National Heart ◽  
Percutaneous Balloon ◽  
History Of ◽  
Mitral Valvotomy ◽  
The Mean ◽  
Procedural Success ◽  
Rheumatic Heart

Background and Aim: Percutaneous balloon mitral valvotomy is well established as safe and effective procedure for patients with mitral stenosis due to Rheumatic Heart Disease. There are some retrospective studies on safety and efficacy of it in different subgroups of patients from our centre. Our study aims to assess the safety, efficacy and outcome of it in Shahid Gangalal National Heart Centre, Kathmandu, Nepal. Methods: A Single centre, prospective study was conducted from July 1st 2013 to June 31st 2014 in our centre. All the patients who underwent percutaneous balloon mitral valvotomy for moderate to severe mitral stenosis during the study period were included. Safety and efficacy of the procedure was analyzed. Results: There were 262 patients enrolled in the study among which 194 (74%) were females. Mean age of patients was 33.2±12.5 years. Seventy patients (26.7%) were in atrial fibrillation, six (2%) were pregnant, three (1%) had history of stroke, twelve (4.6%) underwent previous surgical or balloon commissurotomy. The mean left atrial pressure reduced from 26.8 ± 8.9 mmHg to 15.6 ± 7.2 mmHg (p < 0.05).The mean mitral valve area increased from 0.9 ± 0.17 cm2 to 1.6 ± 0.28 cm2 (p < 0.05). Forty nine patients (18.7%) developed moderate to severe mitral regurgitation. There was no mortality related to the procedure. The procedural success was achieved in 84% patients. Conclusion: Our study suggests that percutaneous balloon mitral valvotomy is a safe and effective procedure for symptomatic mitral stenosis patients.DOI: http://dx.doi.org/10.3126/njh.v12i1.12325 Nepalese Heart Journal Vol.12(1) 2015: 11-14 

scholarly journals Percutaneous balloon mitral valvuloplasty in comparison with open mitral valve commissurotomy for mitral stenosis during pregnancy

2001 ◽  
Vol 37 (3) ◽  
pp. 900-903 ◽  
Author(s):  
José A.M de Souza ◽  
Eulogio E Martinez ◽  
John A Ambrose ◽  
Claudia M.R Alves ◽  
Daniel Born ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Mitral Stenosis ◽  
Mitral Valvuloplasty ◽  
Percutaneous Balloon Mitral Valvuloplasty ◽  
Percutaneous Balloon

scholarly journals Immediate Results of Percutaneous Trans-Luminal Mitral Commissurotomy in Pregnant Women with Severe Mitral Stenosis

2012 ◽  
Vol 6 ◽  
pp. CMC.S8580 ◽  
Author(s):  
Seyfollah Abdi ◽  
Negar Salehi ◽  
Babak Ghodsi ◽  
Hossein Ali Basiri ◽  
Mahmoud Momtahen ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Pregnant Women ◽  
Mitral Stenosis ◽  
Heart Diseases ◽  
Harmful Effect ◽  
Mitral Valve Area ◽  
Valvular Heart Diseases ◽  
Non Surgical Treatment ◽  
Rheumatic Heart ◽  
Valve Area

Background Valvular heart diseases and mainly rheumatic heart diseases complicate about 1% of pregnancies. During pregnancy physiological hemodynamic changes of the circulation are the main cause of mitral stenosis (MS) decompensation. Prior to introduction of percutaneous mitral balloon commissuroplasty (PTMC), surgical comissurotomy was the preferred method of treatment in patients with refractory symptoms. PTMC is an established non-surgical treatment of rheumatic mitral stenosis. The study aimed to assess the safety and efficacy of PTMC in pregnant women with severs mitral stenosis. Material and Method Thirty three consecutive patients undergoing PTMC during pregnancy enrolled in this prospective study. Mitral valve area (MVA), transmitral valve gradient (MVG), and severity of mitral regurgitation (MR) were assessed before and 24 hour after the procedure by transthoracic and transesophageal echocardiography. Mitral valve morphology was evaluated before the procedure using Wilkin's criteria. Patient followed for one month and neonates monitored for weight and height and adverse effect of radiation. Result Mitral valve area increased from 0.83 ± 0.13 cm2 to 1.38 ± 0.29 cm2 ( P = 0.007). Mean gradient of mitral valve decreased from 15.5 ± 7.4 mmHg to 2.3 ± 2.3 mmHg ( P = <0.001). Pulmonary artery pressure decreased from 65.24 ± 17.9 to 50.45 ± 15.33 ( P = 0.012). No maternal death, abortion, intrauterine growth restriction was observed and only one stillbirth occurred. Conclusion PTMC in pregnant women has favorable outcome and no harmful effect on children noted.

Warfarin induced Ovarian Haematoma Mimicking Torsion Ovarian Tumour

2020 ◽  
Vol 7 (2) ◽  
pp. 01-05
Author(s):  
Paapa Dasari
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Adnexal Mass ◽  
Ovarian Tumour ◽  
Dose Titration ◽  
Doppler Flow ◽  
Pain Abdomen ◽  
International Normalised Ratio ◽  
History Of ◽  
Rheumatic Heart

Warfarin toxicity presenting as acute abdomen in a woman with chronic anticoagulation is rare. A 29 year old woman with Rheumatic heart disease with history of  mitral Valve replacement who was on anticoagulation with warfarin presented with pain abdomen  of 2 weeks duration and she was  clinically diagnosed as torsion ovarian cyst. On USG abdomen there was a complex adnexal mass of 6x8 cms with Doppler flow. Her International Normalised Ratio was more than 10 and hence a diagnosis of Ovarian haematoma was entertained and she was managed medically with dose titration of anticoagulants and her pain abdomen subsided and she was discharged home after normalising her International normalised ratio and laparotomy was thus avoided.

scholarly journals Giant Left Atrium in a case of Mitral stenosis with LA thrombus: A Case Report

2016 ◽  
Vol 9 (1) ◽  
pp. 73-74
Author(s):  
Jubayer Ahmad ◽  
Md Mokhlesur Rahman ◽  
Heemel Saha ◽  
Md Aftabuddin ◽  
Asit Baran Adhikary
Keyword(s):  
Case Report ◽  
Mitral Valve ◽  
Left Atrium ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Male Patient ◽  
Mitral Valve Disease ◽  
Mitral Stenosis ◽  
History Of ◽  
Giant Left Atrium

A 52 year-old male patient of severe MS with mild MR with AF with a giant left atrium (LA size 70 mm) and history of CMC presented with symptoms. Giant left atrium is a condition characterized by huge enlargement of the left atrium with a diameter exceeding 65mm. It is most commonly associated with long standing rheumatic mitral valve disease. The patient underwent successful mitral valve replacement and removal of LA thrombus and discharged from hospital with adviceCardiovasc. j. 2016; 9(1): 73-74

scholarly journals Controlled Trial of Sulfinpyrazone in Rheumatic Heart Disease. Preliminary Results

1977 ◽  
Author(s):  
Peter Steele ◽  
Joseph Rainwater ◽  
Edward Genton
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Survival Time ◽  
Rheumatic Heart Disease ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Controlled Trial ◽  
Preliminary Results ◽  
History Of ◽  
Rheumatic Heart

Platelet survival time (SURV) has correlated with a history of thromboembolism (TE) in patients with rheumatic heart disease (RHD). A controlled trial of sulfinpyrazone (SFP) in RHD is in progress and 138 patients have been entered. SURV (51Chromium labelling) was shortened (2.3 ± 0.08 days; AVE t 1/2 ± SEM; normal 3.7 ± 0.04 days) in 40 of 41 (98%) with a history of TE and in 76 of 97 (78%) (2.9 ± 0.07 days; P<0.001) of those without a history of TE. One hundred sixteen with shortened SURV have been randomized to SFP or placebo and 67 have either completed four years (N=37), undergone mitral valve replacement (N=18) (ave 19 months; range 6-32 months), had definite TE (N=8) (average 14 months; range 8-23 months) or died (N=4) (average 15 months; range 5-22 months). Definite TE (prolonged neurologic deficit) occurred in one on SFP and in seven on placebo (all with shortened SURV) (X2 = 4.31; NS). SFP increased SURV (2.4 ± 0.12 to 2.7 ± 0.13 days; N=23; P<0.001) and 12 (52%) had an increase in SURV of >0.02 days. The patient on SFP with new TE had no change in SURV (2.3 to 2.3 days). Placebo did not alter SURV (2.4 ± 0.15 to 2.5 ± 0.08 days; N=26; NS) and two (8%) had an alteration of SURV by > 0.02 days. SURV was not altered in patients with normal SURV (3.7 ± 0.08 to 3.6 ± 0.08 days; N=12; NS) and no patient with normal SURV has had shortened SURV on subsequent yearly measurement. Patients with normal SURV were not randomized. Results suggest that SURV is shortened in patients with RHD who have had or will have TE, that SFP increases SURV and may prevent TE in these patients.

Sign in / Sign up

Export Citation Format

Share Document